Related by context. All words. (Click for frequent words.) 75 Improves Outcomes 74 Renal Artery 73 Acute Myocardial Infarction 73 Patients Receiving 73 Patients Treated With 73 Reduces Mortality 73 Prolongs Survival 73 Heart Failure Patients 73 Patients Undergoing 73 Ischemic Stroke 72 Myocardial Ischemia 72 Severe Sepsis 72 ST Elevation Myocardial 72 Improves Survival 72 Newly Diagnosed Multiple Myeloma 72 Thromboembolism 72 Venous Thromboembolism 72 Prospective Randomized 72 Acute Coronary Syndromes 72 Pooled Analysis 72 Acute Ischemic Stroke 71 Fondaparinux 71 Oral Fingolimod 71 Coronary Artery Bypass Graft 71 Dual Antiplatelet Therapy 71 Advanced Melanoma 71 Myocardial Infarction Study 71 Improve Survival 71 Appears Safe 71 Is Well Tolerated 71 Overactive Bladder 71 ST Segment Elevation 71 Microalbuminuria 71 Combination Treatment 71 Peripheral Arterial 71 Metastatic Prostate Cancer 71 Adjuvant Chemotherapy 71 Pulmonary Arterial Hypertension 70 Chronic Heart Failure 70 NSTEMI 70 Study Demonstrates 70 Risk Stratification 70 Phase 2b Clinical Trial 70 Relapsing Multiple Sclerosis 70 Shows Promise Against 70 Platelet Inhibition 70 Ischemic 70 Clinical Trial Evaluating 70 Previously Treated 70 Liver Failure 70 Carotid Revascularization Endarterectomy vs. 70 Cardiovascular Events 70 Treatment Naive Patients 70 Plaque Psoriasis 70 Relapsing Remitting Multiple Sclerosis 70 Shows Efficacy 70 Long Term Efficacy 70 Well Tolerated 70 Bone Metastases 70 Decompensated Heart Failure 70 Antiplatelet Therapy 70 Septic Shock 70 Demonstrates Efficacy 70 Chronic Renal Failure 70 Soft Tissue Sarcoma 69 Elderly Patients 69 Renal Cell Carcinoma 69 Patients Treated 69 Unfractionated Heparin 69 Reperfusion Injury 69 Renal Impairment 69 Adjunctive 69 Unstable angina 69 Adjuvant Therapy 69 Hypercholesterolemia 69 Adjuvant Treatment 69 Acute Exacerbations 69 Hemodialysis Patients 69 Postmenopausal 69 R lenalidomide 69 Hospital Acquired Pneumonia 69 Pediatric Patients 69 Progressive Multifocal Leukoencephalopathy 69 Nesiritide 69 Antitumor Activity 69 Patient Outcomes 69 Rheumatoid Arthritis Patients 69 Endometrial Cancer 69 Subgroup Analysis 69 Bosutinib 69 Catheter Associated 69 Bivalirudin 69 Idiopathic Pulmonary Fibrosis 69 Treated Patients 69 NIDDM 69 Refractory Hodgkin Lymphoma 68 Demonstrates Significant 68 Infarction 68 Hormone Receptor Positive 68 Demonstrates Positive 68 Cardiotoxicity 68 #-# Full Text 68 Cholesterol Levels SPARCL 68 Val HeFT 68 Heterozygous Familial Hypercholesterolemia 68 Allergic Rhinitis 68 Antihypertensive 68 Randomized Double Blind 68 Adjunctive Therapy 68 Lung Injury 68 Carotid Stenting 68 Controlled Trial 68 Anticoagulants 68 metastatic malignant 68 Successfully Treated 68 Cardiac Resynchronization 68 Myelodysplastic Syndrome MDS 68 Sustained Efficacy 68 Completes Enrollment 68 deep venous thromboses 68 Thrombotic 68 Meta Analysis 68 Invasive Breast Cancer 68 Nebulized 68 receiving VELCADE 68 Breast Cancer Recurrence 68 unstable angina UA 68 Investigational Treatment 68 Meets Primary Endpoint 68 Left Ventricular Dysfunction 68 Acute Decompensated Heart Failure 68 Thrombolysis 68 Orthostatic Hypotension 68 Clinical Evaluation 68 Percutaneous Coronary Intervention 68 Prevent Stroke 68 Complicated Skin 68 Phase III Trial 68 Teva Provides Update 68 Demonstrates Sustained 68 II Clinical Trial 68 Antiplatelet 68 J Am Coll 68 Hypotension 68 Pivotal Phase III 68 dual endothelin receptor antagonist 68 Hormone Refractory Prostate Cancer 68 Phase III Clinical Trial 68 Thromboembolic 68 Controlled Study 68 Exacerbation 68 Diabetic Foot Ulcer 68 Clinical Efficacy 68 Stent Thrombosis 68 Mg Usa 68 Hormone Therapy 68 Randomized Trials 68 Drug Shows Promise 68 Investigational Compound 68 Completes Patient Enrollment 68 Severe Asthma 68 Infected Patients 68 unfractionated heparin UFH 68 Drug Prevents 68 Patency 68 Randomized Evaluation 68 Lowers Risk 68 Fungal Infections 68 Reduced Risk 68 Paroxysmal Nocturnal Hemoglobinuria PNH 68 Study Evaluating 67 Knee Osteoarthritis 67 NOLVADEX 67 Aortic Stenosis 67 Observational Study 67 Multicenter 67 Primary Hypercholesterolemia 67 Begins Dosing 67 See CLINICAL PHARMACOLOGY 67 Non Alcoholic Fatty 67 Phase 2b Study 67 Diabetic Patients 67 Renal Function 67 Clinical Trial Results 67 myocardial infarction ventricular fibrillation 67 Cardiovascular Outcomes 67 Preclinical Data 67 Inhaled Corticosteroids 67 Prevent Heart 67 ACE Inhibitors 67 Comorbidities 67 Statin Therapy 67 Cholesterol Lowering Drug 67 Suicidality 67 Systemic Lupus Erythematosus SLE 67 Anthracycline 67 Treating Chronic 67 Benign Prostatic Hyperplasia 67 Secondary Hyperparathyroidism 67 Treatment Reduces 67 Anti Tumor Activity 67 Metastatic Colorectal Cancer 67 citalopram Celexa 67 Hypertensive Patients 67 Combination REOLYSIN R 67 Aortic Valve Replacement 67 Mitral Regurgitation 67 Relapsed Multiple Myeloma 67 Statistically Significant 67 Resistant Hypertension 67 Chronic Hepatitis C 67 FDA Approvals 67 Initiates Clinical Trial 67 Systemic Sclerosis 67 CLARITY TIMI 67 Less Invasive 67 recurrent glioblastoma multiforme 67 Randomized Study 67 Coronary Arteries 67 Node Positive 67 Phase IIb Clinical Trial 67 Castration Resistant Prostate Cancer 67 Intracerebral Hemorrhage 67 Treatment Shows Promise 67 Diabetic Neuropathy 67 headache abdominal pain 67 Localized Prostate Cancer 67 Aggressive Reduction 67 Lupus Nephritis 67 Thyroid Cancer 67 Recurrent Glioblastoma 67 Tumor Growth 67 Treating Heart Failure 67 Phase 2b Trial 67 Monotherapy 67 Novel Oral 67 Kidney Failure 67 Combo Therapy 67 Randomized Controlled Trials 67 evaluating mipomersen 67 Therapy Shows Promise 67 Refractory Angina 67 Malignant Melanoma 67 Aneurysm Repair 67 Randomized Controlled Trial 67 Ventricular Tachycardia 67 Prophylactic Treatment 67 Recurrent Breast Cancer 67 Slow Progression 66 Antipsychotic 66 Postmenopausal Women 66 Platinol ® 66 Unresectable 66 Venous Thrombosis 66 Postmenopausal Osteoporosis 66 Asymptomatic 66 Initiates Phase III 66 Pegylated Liposomal Doxorubicin 66 Tyrosine Kinase Inhibitor 66 Cardiogenic Shock 66 induce orthostatic hypotension 66 Acute Coronary 66 HER2 Positive Breast Cancer 66 Myocardial Infarction 66 Achieves Primary Endpoint 66 ARCOXIA 66 Survival Benefit 66 Osteoporosis Drug 66 Psychiatric Disorders 66 moderate hepatic impairment 66 Cypher Sirolimus 66 Postherpetic Neuralgia 66 ExTRACT TIMI 66 Myelofibrosis 66 relapsed MM 66 Single Dose 66 Advanced Prostate Cancer 66 HER2 Positive 66 Radical Prostatectomy 66 Atypical Hemolytic Uremic Syndrome 66 Restenosis 66 Hepatotoxicity 66 Anticoagulation 66 Disease Progression 66 Increased Mortality 66 Enoxaparin 66 Significantly Improves 66 Significantly Reduces 66 Cutaneous T 66 Hyperlipidemia 66 Diffuse Large B 66 Coronary Angiography 66 undergoing elective percutaneous 66 Carotid Artery Stenting 66 Subarachnoid hemorrhage 66 Warfarin Coumadin 66 Stable Angina 66 Reduces Risk 66 recurrent DVT 66 Advanced Renal Cell 66 Ventricular Arrhythmias 66 Osteoporosis Drugs 66 Carotid Endarterectomy 66 bone marrow reticulin deposition 66 Adenoma 66 β blockers 66 First Patient Enrolled 66 Occlusive Disease 66 Acute Coronary Syndromes ACS 66 Renal dysfunction 66 Ranolazine 66 Treatment Resistant 66 Breast Cancer Treatment 66 Previously Untreated 66 Chronic Sinusitis 66 Subtypes 66 Pivotal Trial 66 Urinary Incontinence 66 Myelodysplastic Syndromes 66 heparin induced thrombocytopenia 66 Proves Effective 66 Levels Linked 66 Clinical Trial Data 66 Pivotal Clinical Trial 66 Prognostic Significance 66 Clinical Outcomes 66 dalteparin 66 infarction NSTEMI 66 Tigecycline 66 Genes Linked 66 Adenomas 66 Genes Predict 66 Erythropoietic therapies may 66 Artery Disease 66 Fracture Risk 66 Peptic Ulcer 66 Generalized Anxiety Disorder 66 Dose Ranging Study 66 CYT# potent vascular disrupting 66 Drug Eluting 66 zoledronic acid Reclast 66 oral antidiabetic medication 66 Intracranial 66 ORLive Presents 66 ritonavir boosted 66 Demonstrate Significant 66 alfuzosin 66 TO AVOID PREGNANCY WHILE 66 Shows Promising 66 Non Alcoholic Steatohepatitis 66 Initiates Enrollment 66 unstable angina pectoris 66 Bloodstream Infections 66 Prostate Biopsy 66 Clinical Outcome 66 Chemoradiation 66 Kidney Transplant Recipients 66 Autologous Stem Cell Transplantation 66 Telithromycin 66 Angioedema 66 cisplatin gemcitabine 66 Breast Cancers 66 aldosterone antagonists 66 Acute Heart Failure 66 myelodysplastic myeloproliferative diseases 66 Postmarketing 66 Metastatic Renal Cell Carcinoma 66 Demonstrated Significant 66 Relapsed Refractory 66 Study Indicates 66 Percutaneous Tibial Nerve Stimulation 66 Anticoagulant 66 Predict Response 65 J Am Acad 65 Liver Metastases 65 Skin Lesions 65 Valvular 65 Neoadjuvant 65 Cancer Incidence Mortality 65 CLINICAL PHARMACOLOGY 65 Diabetic Nephropathy 65 number NCT# ClinicalTrials.gov 65 Chronic Hepatitis B 65 Laryngeal Cancer 65 venous thromboembolic disease 65 evaluating tivozanib 65 Immunosuppression 65 Lipid Lowering Treatment 65 Phase IIb Trial 65 HCV Protease Inhibitor 65 Chemotherapeutic Agents 65 Acute Coronary Syndrome 65 leukopenia pancytopenia thrombocytopenia 65 Pharmacokinetics PK 65 Drug Resistant 65 Bucindolol 65 Adenoma Prevention 65 Differential Diagnosis 65 Mg Uk 65 Acute Renal Failure 65 INSPIRE Trial Phase III 65 PLX STROKE targeting 65 Prostate Cancer Patients 65 headache nasopharyngitis 65 Low Dose 65 Drug Combo 65 Multidrug 65 Boosts Survival 65 receiving XGEVA 65 Phase Ib Clinical Trial 65 Breast Cancer Patients 65 Hernia Repair 65 Paroxysmal Nocturnal Hemoglobinuria 65 Genes Associated 65 Liver Injury 65 Presents Positive 65 FluCAM arm 65 See WARNINGS 65 CIMZIA TM certolizumab pegol 65 CT Angiography 65 LYSTEDA 65 Accelerated Partial Breast Irradiation 65 Investigational Drug 65 Confirms Efficacy 65 PEGylated interferon beta 1a 65 Predict Risk 65 Minimally Invasive Treatment 65 Gastric Cancer 65 Infarct 65 Study Showed 65 IMPACT DCM 65 Patient Enrollment 65 Protease Inhibitors 65 Initiate Clinical Trial 65 Systematic Review 65 Phase 2a Trial 65 Maven Semantic 65 Radiofrequency Ablation 65 Receives Orphan Drug Designation 65 Folfox 65 Breast Carcinoma 65 Drug Candidate 65 Trial Evaluating 65 Prognostic Value 65 Atopic Dermatitis 65 Stent Implantation 65 Zoledronic Acid 65 invasive aspergillosis 65 aspirin clopidogrel 65 elevated transaminases 65 Combination Therapy 65 ATACAND 65 Randomized Double blind 65 Intracranial Aneurysms 65 Randomized Phase 65 NICE Recommends 65 death dissection perforation 65 Presents Preclinical Data 65 serum phosphorous 65 papillary renal cell carcinoma 65 Initiates Phase II 65 Hepatitis C Genotype 65 Lung Cancers 65 Left Ventricular 65 Renal Insufficiency 65 STENT 65 Schizophrenia Treatment 65 Atherosclerotic 65 Idiopathic 65 Obese Patients 65 Myelodysplastic Syndrome 65 transcranial Doppler ultrasound 65 Increased Risk 65 Inhaled Nitric Oxide 65 Blood Clots 65 Paclitaxel Eluting 65 Intervention Effectiveness 65 Embolic Protection Device 65 Non Responders 65 Inflammatory Arthritis 65 Intravitreal 65 sitagliptin metformin 65 Hsp# Inhibitor 65 Nicotine Vaccine 65 epoetin alpha 65 Significantly Improved 65 EURIDIS 65 Hepatocellular Carcinoma 65 Initiate Phase 65 Orally Active 65 Rotavirus Vaccine 65 Intracoronary 65 Atrial 65 Osteoarthritis Patients 65 ß blockers 65 Uterine Fibroids 65 polycythemia vera essential thrombocythemia 65 Contrast Enhanced 65 Prostate Cancer Treatment 65 Virus Linked 65 Phase III multicenter 65 Slows Progression 65 thrombocytosis 65 Colorectal Adenomas 65 Test Detects 65 psoriatic arthritis PsA 65 Angiographic 65 Pharmacologic 65 Prospective Cohort Study 65 Paroxysmal 65 Anticancer Activity 65 R Saizen R 65 Stem Cell Treatment 65 postoperative AF 65 Clopidogrel 65 Tolvaptan 65 Fixed Dose 65 Improved Survival 65 FOLFOX6 chemotherapy regimen 65 Embolization 65 Smoking Linked 65 Inflammatory Markers 65 Percutaneous Transluminal Coronary Angioplasty 65 Arthritis Drug 65 SPRYCEL ® 65 Vaginal Gel 65 5 Fluorouracil 65 Endovascular Treatment 65 Vertebral Fractures 65 Disease Modifying 65 Hyperkalemia 65 Hematologic 65 myocardial infarction hypersensitivity 65 PEGINTRON TM 65 Randomized Phase II 65 Epilepsy Drug 65 Valvular Heart Disease 65 Teriflunomide 65 acute PAO 65 Hepatocellular 65 Neuroendocrine Tumors 65 AA Amyloidosis 65 Allogeneic 65 Tumor Response 65 severe oral mucositis 65 Investigational Agent 65 Hospitalized Patients 65 Angiotensin Converting Enzyme 65 recurrent malignant glioma 65 Solid Tumors 65 Cimzia TM 65 Hemolysis 65 Chronic HCV 65 NAVISTAR R 65 Clostridium difficile Infection 65 Arterial Disease 65 Mouse Model 65 Vaccine Protects Against 65 Ribavirin causes 65 Organ Rejection 65 Non inferiority 64 Adverse Event 64 CYP#A# substrate 64 Fluorouracil 64 Metabolic Efficiency 64 morphometric vertebral fractures 64 Stress Incontinence 64 Kidney Transplant Patients 64 aripiprazole Abilify 64 GP IIb IIIa inhibitors 64 Sipuleucel T 64 Increases Risk 64 Treatment Naive HIV 64 Significantly Reduced 64 hypertrichosis occurred 64 Treatment Regimen 64 Neoadjuvant Chemotherapy 64 ® lenalidomide 64 Hemorrhagic Stroke 64 venlafaxine Effexor 64 Hepatitis C Virus 64 Hepatic Encephalopathy 64 Venous thromboembolism 64 Randomized Controlled 64 Intracerebral 64 antiplatelet medications 64 biliary tract cancer 64 MGd 64 Leukemias 64 Bronchiectasis 64 Antiviral Therapy 64 Moxifloxacin 64 Post Operative 64 Hip Fractures 64 Launches Generic Version 64 Enlarged Prostate 64 Malignant Glioma 64 Hypertrophy 64 Investigational Oral 64 Newly Diagnosed 64 Pafuramidine 64 Raloxifene Evaluation MORE 64 Overactive Bladder OAB 64 severe neutropenia 64 imipramine Tofranil 64 Drug Eluting Stents 64 Placebo Controlled Trial 64 Targeted Therapy 64 Who Underwent 64 Acute Stroke 64 receiving INTRON 64 First Patient Treated 64 receiving golimumab 64 Sentinel Lymph Node Biopsy 64 Left Ventricular Hypertrophy 64 TNF Blockers 64 chronically immunosuppressed solid 64 reinfarction 64 Nilotinib 64 Chronic Bronchitis 64 Preclinical Models 64 complement inhibitor eculizumab 64 Diastolic Heart Failure 64 Multicenter Study 64 ergot derivatives 64 Estrogen Therapy 64 Robotic Assisted 64 Oral Calcitonin 64 STRIDE PD 64 Treatment Outcome 64 Therapy Reduces 64 Fingolimod 64 Bone Fractures 64 mild hepatic impairment 64 Known hypersensitivity 64 Phase IIa Clinical Trial 64 Esophageal 64 Aortic Valve 64 Therapy Improves 64 BARACLUDE ® 64 Prospective Multicenter 64 Thrombocytopenia 64 HALTS 64 Cell Lymphoma 64 Nonalcoholic Fatty Liver Disease 64 Endarterectomy 64 Treatment Experienced 64 INTEGRILIN R 64 Adalimumab 64 REMINDER ORLive Presents 64 Obesity Linked 64 ZOLINZA 64 Partial Onset Seizures 64 Pivotal Study 64 Abciximab 64 Cervical Dysplasia 64 Aliskiren 64 Versus Placebo 64 Prognostic Factors 64 Ischaemic 64 PEG IFN 64 atherosclerotic renal artery stenosis 64 Desvenlafaxine Succinate 64 Chronic Constipation 64 Neovascular Age Related Macular 64 RECORD1 64 Successfully Treats 64 Stent Restenosis 64 Recurrent Stroke 64 Androgen Deprivation Therapy 64 Inflammatory Disease 64 Mylan Receives Approval 64 Surgical Treatment 64 Serious Infections 64 LHRH receptor positive 64 moderate renal impairment 64 Induction Therapy 64 FASLODEX 64 ILLUSTRATE 64 Pivotal Phase 64 Related Mortality 64 FUSILEV enhances 64 erythematosus 64 IN PATIENTS WITH 64 essential thrombocythemia ET 64 hyperplasia BPH 64 Bacteremia 64 Glycemic Control 64 Efficacy Trial 64 Multicenter Randomized 64 neutropenia dehydration dyspnea 64 Diagnostic Criteria 64 See CONTRAINDICATIONS 64 Panic Disorder 64 non valvular atrial 64 Help Predict 64 Urinary Tract Infections 64 chronic idiopathic thrombocytopenic purpura 64 Geodon ziprasidone 64 Polyneuropathy 64 Catheter Ablation 64 Bare Metal Stent 64 Afib 64 CLINICAL STUDIES 64 Emerging Therapies 64 Tiotropium 64 Phase 2a Clinical Trial 64 invasive candidiasis 64 Pegylated Interferon 64 Double Blind Placebo 64 Respiratory Virus 64 Cardiol 64 Naive Patients 64 Deforolimus 64 carotid artery stenting CAS 64 nicardipine 64 Submits NDA 64 Advanced Ovarian Cancer 64 Lupus Drug 64 Renal Cell Carcinoma RCC 64 Pneumococcal Vaccine 64 Heart Transplant Recipients 64 Acute Myocardial 64 Beta Blocker 64 endometrial hyperplasia 64 treat benign prostatic 64 Hydroxyurea 64 adalimumab Humira 64 JAK2 Inhibitor 64 CALGB # [002] 64 Confirmatory Phase 64 thalidomide Thalomid 64 Bipolar Mania 64 Preclinical Study 64 Beta Blockers 64 Bosentan 64 Chronic Pelvic Pain 64 Metabolic Disease 64 LENALIDOMIDE 64 sunitinib Sutent 64 Irbesartan 64 Lung Cancer Trial 64 Initiates Phase 2b 64 Pancreatic Adenocarcinoma 64 CYP#A# CYP#D# 64 Study Shows Promise 64 Renal Cancer 64 ACUITY trial 64 CAPRIE 64 Showed Significant 64 Depressive Symptoms 64 Community Acquired Pneumonia 64 Remission Maintenance 64 bisoprolol 64 paroxetine Paxil 64 drug eluting stent implantation 64 Endothelial Function 64 Advanced Heart Failure 64 Files IND 64 Improves Quality 64 Granted Orphan Drug 64 prospectively stratified 64 cyclophosphamide methotrexate 64 Chronic Myeloid Leukemia 64 vapreotide acetate 64 Valsartan 64 Rheumatoid 64 NDA Submission 64 Kidney Function 64 GW# [003] 64 MEND CABG 64 Antigen Specific 64 leiomyomas 64 Genetic Marker 64 Transplant Rejection 64 sustained ventricular tachycardia 64 Irritable Bowel 64 metastatic pancreatic 64 Lung Cancer Patients 64 Crit Rev 64 Effective Than 64 Circulatory Support 64 Anemia Drug 64 symptomatic intracranial 64 icatibant 64 infusional 64 Ziprasidone 64 bronchial hyperresponsiveness 64 included exfoliative dermatitis 64 Peginterferon 64 Reduces Pain 64 CYP#D# inhibitor 64 Arrhythmias 64 Transcatheter 64 Blood Thinner 64 Bare Metal Stents 63 alfa 2a 63 Guidelines Issued 63 ACTOS ® 63 Polymerase Inhibitor 63 Often Misdiagnosed 63 RE LY 63 Chronic Liver Disease 63 vincristine doxorubicin 63 Endocarditis 63 Atorvastatin Evaluation 63 Symptom Relief 63 stable angina pectoris 63 catheter occlusion 63 distal embolization thrombus formation 63 Contrast Agent 63 Aflibercept 63 FDA Okays 63 colorectal adenoma 63 severe exacerbations 63 Patients Suffering 63 Simulect 63 Corticosteroid 63 Eculizumab 63 ischemic complications 63 CABG Surgery 63 BENICAR HCT 63 somnolence dizziness 63 GOUT 63 Aortic Dissection 63 hyperphenylalaninemia HPA due 63 Migraine Headaches 63 Juvenile Idiopathic Arthritis 63 Postmenopausal hormone therapy 63 thromboembolic events 63 Eluting Stent 63 Malignancies 63 Urine Test 63 metastatic neuroendocrine tumors 63 Phase III AFFIRM 63 Beneficial Effects 63 CARDIOVASCULAR 63 Improve Outcomes 63 Embolic 63 J Clin 63 lenalidomide Revlimid R 63 Dupuytren Disease 63 Follicular Lymphoma 63 Acute Migraine 63 Anti Tumor 63 NATRECOR R 63 Platinol ® cisplatin 63 bullous 63 Treatment Naive 63 Renal Anemia 63 FDA APPROVES 63 sorafenib Nexavar 63 Hydralazine 63 disease GERD 63 Sapacitabine 63 LAB CGRP 63 Contraindications 63 Malformations 63 B Cell Lymphoma 63 Spinal Fusion 63 NSABP B 63 Endocrine Therapy 63 Tyrosine Kinase Inhibitors 63 Oral Cladribine 63 ThermoDox R 63 mild renal insufficiency 63 Sleep Disturbances 63 Temsirolimus 63 Gene Linked 63 Carotid 63 Nymox NX 63 Intravesical 63 Physician Insights 63 Rectal Cancer 63 ulcerative colitis Crohn disease 63 NMIBC 63 Antiviral Activity 63 PICSO ® 63 Surgical Procedures 63 Stent Placement 63 clevidipine 63 IIIa inhibitor 63 Newly Diagnosed Patients 63 CARE HF 63 Vulvar 63 dermatologic reactions 63 Advanced Colorectal Cancer 63 Benign Prostatic Hyperplasia BPH 63 Esophageal Cancer 63 Intravenous immunoglobulin 63 Pegloticase 63 Immunomedics Announces 63 NATRECOR ® 63 Bipolar Depression 63 Gets FDA Clearance 63 Valve Replacement 63 Deep Venous Thrombosis 63 Carcinomas 63 Montelukast 63 ACTEMRA TM 63 Immunomodulatory 63 Randomized Clinical Trial 63 hypophosphatemia 63 Fluvastatin 63 arterial thromboembolic 63 5q MDS 63 Cilostazol 63 antithrombotic therapy 63 Genetic Markers 63 Gene Mutation 63 Dementia Related Psychosis 63 DES implantation 63 Skeletal Muscle 63 Protease Inhibitor 63 Exacerbations 63 BZA CE 63 AVAPRO 63 Dialysis Patients 63 reduce serum phosphate 63 Xelox 63 multicenter prospective 63 Antidepressants Linked 63 Edge STudy 63 Relapsed Refractory Multiple Myeloma 63 Trandolapril 63 Hip Fracture 63 Autoimmune Disease 63 Prolongs Life 63 Celecoxib APC trial 63 Metastatic Melanoma 63 ZACTIMA 63 Eur J 63 Diabetic Ulcers 63 Stable Coronary Artery 63 carotid endarterectomy CEA 63 Guideline Update 63 Prostatectomy 63 Decompensated 63 Cardiac Resynchronization Therapy 63 Colorectal Cancer Patients 63 Minimally Invasive Procedure 63 Replacement Therapy 63 Vildagliptin 63 oropharyngeal candidiasis OPC 63 intravascular hemolysis 63 fluvastatin 63 Myeloma Patients 63 Strongly Linked 63 Epoetin Alfa 63 Interferon beta 1a 63 Ovarian Cancer Patients 63 atypical Hemolytic Uremic Syndrome 63 Brain Tumors 63 severe hypersensitivity reactions 63 Cyclophosphamide 63 allogeneic hematopoietic stem cell 63 keloid scarring 63 Coronary Artery 63 IIa Clinical Trial 63 Magnetic Stimulation 63 Breast Density 63 somatostatin analog 63 Preterm Labor 63 myopathy rhabdomyolysis 63 Insulin Resistance 63 Brain Atrophy 63 Immune Responses 63 Uterine Fibroid Embolization 63 Cardiovascular Disease Risk 63 Enzastaurin 63 Vidaza ® 63 undergoing Percutaneous Coronary 63 Brain Metastases 63 Critically Ill Patients 63 Oral Cavity 63 Novel Compound 63 Oral Mucositis 63 Uterine Cancer 63 Parathyroid Hormone 63 Drug Fails 63 patients undergoing percutaneous 63 Long Term Outcomes 63 NSTE ACS 63 tumor lysis syndrome 63 ventricular tachyarrhythmia 63 Asthma Treatment 63 Colorectal Cancers 63 Helps Predict 63 Arrhythmogenic 63 fosbretabulin 63 Effectively Treats 63 haematologic 63 Oral Formulation 63 Kinase Inhibitor 63 Myocardial Perfusion Imaging 63 Cholesterol Drug 63 Transdermal Patch 63 Virus Infection 63 Cognitive Impairment